Ratings Fermentalg

Equities

ALGAE

FR0011271600

Real-time Euronext Paris Other stock markets 16:35:00 30/04/2024 BST			5-day change	1st Jan Change
0.573 ^EUR	-.--%		-3.21%	+89.74%

04-12	Fermentalg: transfer to Euronext Growth on April 16	CF
04-04	Fermentalg SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The group usually releases upbeat results with huge surprise rates.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
FERMENTALG	+89.74%	25.24M	-
IQVIA HOLDINGS INC.	+0.17%	42.19B	B
MODERNA, INC.	+10.92%	42.24B	B-
LONZA GROUP AG	+44.30%	40.15B	A
CELLTRION, INC.	-6.20%	28.31B	C
ICON PUBLIC LIMITED COMPANY	+5.23%	24.63B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.2B	B
MEDPACE HOLDINGS, INC.	+26.69%	12.01B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+6.57%	10.4B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes